| Rx0000101 |
Par Pharmaceutical |
12/31/2021 |
67979051143 |
Aveed, 750 mg/3mL (250mg/1mL) solution, single use vial |
10/01/2021 |
68.72 |
1485.55 |
05/08/2027 |
Single Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration?s Orange Book, as of 7/15/2021. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns N-U blank because they are not applicable to this product. |
| Rx0000101 |
Par Pharmaceutical |
12/31/2021 |
67979000101 |
Valstar, 40 mg/1ml solution, 4x5mL |
10/01/2021 |
339.85 |
7347.10 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The Orange Book indicates that, as of 7/15/2021, the Orange Book database does not contain unexpired patents for this product. As a result, Endo has left the patent expiration date field for this product blank.(3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns N-U blank because they are not applicable to this product. |
| Rx0000101 |
Par Pharmaceutical |
03/31/2021 |
42023016410 |
Vasostrict, Vasopressin IV Soln 20 Unit/ML (For IV Infusion), 1 mL x 10 VL |
02/04/2021 |
148.17 |
2123.77 |
01/30/2035 |
Single Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Par believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration?s Orange Book, as of 4/19/2021. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Par has left the ?Patent Expiration Date? field for this product blank. (3) Par did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Par has left columns N-U blank because they are not applicable to this product. |
| Rx0000101 |
Par Pharmaceutical |
03/31/2021 |
42023016425 |
Vasostrict, Vasopressin IV Soln 20 Unit/ML (For IV Infusion), 1 mL x 25 VL |
02/04/2021 |
370.43 |
5309.43 |
01/30/2035 |
Single Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Par believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration?s Orange Book, as of 4/19/2021. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Par has left the ?Patent Expiration Date? field for this product blank. (3) Par did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Par has left columns N-U blank because they are not applicable to this product. |
| Rx0000101 |
Par Pharmaceutical |
03/31/2021 |
42023019001 |
Vasostrict, Vasopressin IV Soln 20 Unit/ML (For IV Infusion), 10 mL |
02/04/2021 |
148.17 |
2123.77 |
01/30/2035 |
Single Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Par believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration?s Orange Book, as of 4/19/2021. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Par has left the ?Patent Expiration Date? field for this product blank. (3) Par did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Par has left columns N-U blank because they are not applicable to this product. |
| Rx0000101 |
Par Pharmaceutical |
12/31/2021 |
66887000301 |
Xiaflex, 0.9mg powder for solution, single use vial |
10/01/2021 |
204.12 |
5438.01 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The federal Food and Drug Administration?s Purple Book does not require the listing of patents or their expiration dates for any product, including Xiaflex. The patent expiration date for any patent potentially associated with Xiaflex would also depend on pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten such an expiration date. As a result, Endo has left the patent expiration date field for this product blank. (3) For ?Year Introduced?, Endo is providing the year in which first price point is published in the pricing compendia database for the labeler code / product / product presentation. |
| Rx0000006 |
Pfizer |
03/31/2021 |
00005197105 |
Prevnar 13 (pneumococcal 13-valent conjugate vaccine) Injection Rx, 0.5 mL Prefilled Syringe, Pack Size 1 |
01/01/2021 |
10.17 |
217.74 |
11/09/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2021 |
00005197102 |
Prevnar 13 (pneumococcal 13-valent conjugate vaccine) Injection Rx, 0.5 mL Prefilled Syringe, Pack Size 10 |
01/01/2021 |
98.61 |
2111.14 |
11/09/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2021 |
00005010010 |
Trumenba (meningococcal group B vaccine) Injection Rx, 120 mcg/0.5 mL Prefilled Syringe, Pack Size 10 |
01/01/2021 |
74.57 |
1565.99 |
08/27/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2021 |
00005010005 |
Trumenba (meningococcal group B vaccine) Injection Rx, 120 mcg/0.5 mL Prefilled Syringe, Pack Size 5 |
01/01/2021 |
37.29 |
783.00 |
08/27/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2021 |
00069100201 |
Xeljanz (tofacitinib), 10 mg Tablet, 60ct |
01/01/2021 |
230.31 |
4930.49 |
12/08/2025 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2021 |
00069100101 |
Xeljanz (tofacitinib), 5 mg Tablet, 60ct |
01/01/2021 |
230.31 |
4930.49 |
12/08/2025 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2021 |
00069050130 |
Xeljanz XR (tofacitinib), 11mg Tablet, 30ct |
01/01/2021 |
230.31 |
4930.49 |
12/08/2025 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000237 |
Pharmacyclics an AbbVie Company |
03/31/2021 |
57962014012 |
IMBRUVICA(ibrutinib); 140mg capsule; 120 ct |
01/01/2021 |
1370.70 |
19893.69 |
10/24/2034 |
Single Source Drug |
None |
1 |
Pharmacyclics pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by Pharmacyclics to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000237 |
Pharmacyclics an AbbVie Company |
03/31/2021 |
57962014009 |
IMBRUVICA(ibrutinib); 140mg capsule; 90 ct |
01/01/2021 |
1028.03 |
14920.27 |
10/24/2034 |
Single Source Drug |
None |
1 |
Pharmacyclics pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by Pharmacyclics to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000237 |
Pharmacyclics an AbbVie Company |
03/31/2021 |
57962014028 |
IMBRUVICA(ibrutinib); 140mg tablets; 28 ct |
01/01/2021 |
959.49 |
13925.59 |
10/24/2034 |
Single Source Drug |
None |
1 |
Pharmacyclics pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by Pharmacyclics to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000237 |
Pharmacyclics an AbbVie Company |
03/31/2021 |
57962028028 |
IMBRUVICA(ibrutinib); 280mg tablets; 28 ct |
01/01/2021 |
959.49 |
13925.59 |
10/24/2034 |
Single Source Drug |
None |
1 |
Pharmacyclics pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by Pharmacyclics to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000237 |
Pharmacyclics an AbbVie Company |
03/31/2021 |
57962056028 |
IMBRUVICA(ibrutinib); 560mg tablets; 28 ct |
01/01/2021 |
959.49 |
13925.59 |
10/24/2034 |
Single Source Drug |
None |
1 |
Pharmacyclics pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by Pharmacyclics to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000237 |
Pharmacyclics an AbbVie Company |
03/31/2021 |
57962007028 |
IMBRUVICA(ibrutinib); 70mg capsules; 28 ct |
01/01/2021 |
959.49 |
13925.59 |
10/24/2034 |
Single Source Drug |
None |
1 |
Pharmacyclics pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by Pharmacyclics to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000237 |
Pharmacyclics an AbbVie Company |
03/31/2021 |
57962042028 |
IMBRUVICA(ibrutinib);420mg tablets; 28 ct |
01/01/2021 |
959.49 |
13925.59 |
10/24/2034 |
Single Source Drug |
None |
1 |
Pharmacyclics pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by Pharmacyclics to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000236 |
PTC Therapeutics, Inc |
03/31/2021 |
52856050203 |
Emflaza/ 18mg tabs/ 30 ct |
01/18/2021 |
346.74 |
5764.56 |
02/01/2024 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/01/2017 |
Marathon Pharmaceuticals |
75000000 |
None |
The acquisition price of Emflaza was comprised of: (i) $75.0 million in cash and (ii) 6,683,598 shares of PTC Therapeutics common stock, as well as (iii) contingent payments from PTC Therapeutics based on annual net sales of Emflaza beginning in 2018, up to a specified aggregate maximum amount over its expected commercial life, up to $50.0 million, subject to the terms and conditions of the Asset Purchase Agreement |
3925.00 |
0.00 |
2017 |
3925.00 |
None |
We took a 6.4% price increase vs. August and this calculates to the correct amount submitted to MediSpan |
| Rx0000236 |
PTC Therapeutics, Inc |
09/30/2021 |
52856050203 |
Emflaza/ 18mg tabs/ 30 ct |
08/01/2021 |
172.94 |
5937.50 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/01/2017 |
Marathon Pharmaceuticals |
140000000 |
None |
None |
3925.00 |
0.00 |
2017 |
3925.00 |
None |
None |
| Rx0000236 |
PTC Therapeutics, Inc |
03/31/2021 |
52856050522 |
Emflaza/ 22.75mg/mL susp/ 13ml in 30 ml bottle |
01/18/2021 |
253.81 |
4219.51 |
02/01/2024 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/01/2017 |
Marathon Pharmaceuticals |
75000000 |
None |
The acquisition price of Emflaza was comprised of: (i) $75.0 million in cash and (ii) 6,683,598 shares of PTC Therapeutics common stock, as well as (iii) contingent payments from PTC Therapeutics based on annual net sales of Emflaza beginning in 2018, up to a specified aggregate maximum amount over its expected commercial life, up to $50.0 million, subject to the terms and conditions of the Asset Purchase Agreement |
2873.00 |
0.00 |
2017 |
2873.00 |
None |
None |
| Rx0000236 |
PTC Therapeutics, Inc |
09/30/2021 |
52856050522 |
Emflaza/ 22.75mg/mL susp/ 13ml in 30 ml bottle |
08/01/2021 |
126.59 |
4346.10 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/01/2017 |
Marathon Pharmaceuticals |
140000000 |
None |
None |
2873.00 |
0.00 |
2017 |
2873.00 |
None |
None |
| Rx0000236 |
PTC Therapeutics, Inc |
03/31/2021 |
52856050303 |
Emflaza/ 30mg tabs/ 30 ct |
01/18/2021 |
577.93 |
9608.09 |
02/01/2024 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/01/2017 |
Marathon Pharmaceuticals |
75000000 |
None |
The acquisition price of Emflaza was comprised of: (i) $75.0 million in cash and (ii) 6,683,598 shares of PTC Therapeutics common stock, as well as (iii) contingent payments from PTC Therapeutics based on annual net sales of Emflaza beginning in 2018, up to a specified aggregate maximum amount over its expected commercial life, up to $50.0 million, subject to the terms and conditions of the Asset Purchase Agreement |
6542.00 |
0.00 |
2017 |
6542.00 |
None |
None |
| Rx0000236 |
PTC Therapeutics, Inc |
09/30/2021 |
52856050303 |
Emflaza/ 30mg tabs/ 30 ct |
08/01/2021 |
288.24 |
9896.34 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/01/2017 |
Marathon Pharmaceuticals |
140000000 |
None |
None |
6542.00 |
0.00 |
2017 |
6542.00 |
None |
None |
| Rx0000236 |
PTC Therapeutics, Inc |
03/31/2021 |
52856050403 |
Emflaza/ 36mg tabs/ 30 ct |
01/18/2021 |
644.01 |
10706.66 |
02/01/2024 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/01/2017 |
Marathon Pharmaceuticals |
75000000 |
None |
The acquisition price of Emflaza was comprised of: (i) $75.0 million in cash and (ii) 6,683,598 shares of PTC Therapeutics common stock, as well as (iii) contingent payments from PTC Therapeutics based on annual net sales of Emflaza beginning in 2018, up to a specified aggregate maximum amount over its expected commercial life, up to $50.0 million, subject to the terms and conditions of the Asset Purchase Agreement |
7290.00 |
0.00 |
2017 |
7290.00 |
None |
We took a 6.4% price increase vs. August and this calculates to the correct amount submitted to MediSpan |
| Rx0000236 |
PTC Therapeutics, Inc |
09/30/2021 |
52856050403 |
Emflaza/ 36mg tabs/ 30 ct |
08/01/2021 |
749.47 |
11456.13 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/01/2017 |
Marathon Pharmaceuticals |
140000000 |
None |
None |
7290.00 |
0.00 |
2017 |
7290.00 |
None |
None |
| Rx0000236 |
PTC Therapeutics, Inc |
03/31/2021 |
52856050101 |
Emflaza/ 6mg tabs/ 100 ct |
01/18/2021 |
385.26 |
6404.91 |
02/01/2024 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/01/2017 |
Marathon Pharmaceuticals |
75000000 |
None |
The acquisition price of Emflaza was comprised of: (i) $75.0 million in cash and (ii) 6,683,598 shares of PTC Therapeutics common stock, as well as (iii) contingent payments from PTC Therapeutics based on annual net sales of Emflaza beginning in 2018, up to a specified aggregate maximum amount over its expected commercial life, up to $50.0 million, subject to the terms and conditions of the Asset Purchase Agreement |
4361.00 |
0.00 |
2017 |
4361.00 |
None |
None |
| Rx0000236 |
PTC Therapeutics, Inc |
09/30/2021 |
52856050101 |
Emflaza/ 6mg tabs/ 100 ct |
08/01/2021 |
192.15 |
6597.05 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/01/2017 |
Marathon Pharmaceuticals |
140000000 |
None |
None |
4361.00 |
0.00 |
2017 |
4361.00 |
None |
Price increase for all strengths only includes PTC NCD related products. The product was launched in 2017 under Marathon's NDC, 42998, and has since been removed from the market. |
| Rx0000220 |
Puma Biotechnology, Inc. |
03/31/2021 |
70437024018 |
Nerlynx Oral Tablet 40 mg, 180 tablet package |
01/15/2021 |
820.00 |
17515.00 |
12/31/2025 |
Single Source Drug |
14959 |
None |
A number of factors go into the pricing of NERLYNX including manufacturing, sales and marketing costs, and investments in continued research and development. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000220 |
Puma Biotechnology, Inc. |
09/30/2021 |
70437024018 |
Nerlynx Oral Tablet 40 mg, 180 tablet package |
08/01/2021 |
860.00 |
18375.00 |
07/18/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000324 |
PuraCap Labortories LLC dba Blu Pharmaceuticals |
09/30/2021 |
24658077005 |
Sulindac 150mg USP Tabs 500ct Blu |
07/01/2021 |
470.84 |
530.84 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Market Dynamic Change |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Puracap developed the products |
| Rx0000324 |
PuraCap Labortories LLC dba Blu Pharmaceuticals |
09/30/2021 |
24658077105 |
Sulindac 200mg USP Tabs 500ct Blu |
07/01/2021 |
693.70 |
774.70 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Market Dynamic Change |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Puracap developed the products |
| Rx0000056 |
Purdue Pharma LP |
03/31/2021 |
59011075104 |
BUTRANS 10MCG/HOUR TDS 4S |
01/01/2021 |
23.15 |
486.13 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2021 |
59011075804 |
BUTRANS 15 MCG/HOUR TDS 4S |
01/01/2021 |
33.39 |
701.23 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2021 |
59011075204 |
BUTRANS 20MCG/HOUR TDS 4S |
01/01/2021 |
40.98 |
860.61 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2021 |
59011075004 |
BUTRANS 5 MCG/HOUR TDS 4S |
01/01/2021 |
15.43 |
324.08 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2021 |
59011075704 |
BUTRANS 7.5 MCG/HOUR TDS 4S |
01/01/2021 |
21.61 |
453.71 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2021 |
59011027660 |
HYSINGLA ER 100MG TABLETS 60S |
01/01/2021 |
138.98 |
2918.65 |
12/21/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2021 |
59011027760 |
HYSINGLA ER 120MG TABLETS 60S |
01/01/2021 |
154.02 |
3234.39 |
12/21/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2021 |
59011027160 |
HYSINGLA ER 20MG TABLETS 60S |
01/01/2021 |
29.75 |
624.82 |
12/21/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2021 |
59011027260 |
HYSINGLA ER 30MG TABLETS 60S |
01/01/2021 |
43.43 |
912.02 |
12/21/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2021 |
59011027360 |
HYSINGLA ER 40MG TABLETS 60S |
01/01/2021 |
58.51 |
1228.70 |
12/21/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2021 |
59011027460 |
HYSINGLA ER 60MG TABLETS 60S |
01/01/2021 |
81.02 |
1701.36 |
12/21/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2021 |
59011027560 |
HYSINGLA ER 80MG TABLETS 60S |
01/01/2021 |
109.23 |
2293.84 |
12/21/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2021 |
59011041010 |
OXYCONTIN 10MG TABLETS 100S |
01/01/2021 |
21.13 |
443.71 |
03/29/2030 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health. |
| Rx0000056 |
Purdue Pharma LP |
03/31/2021 |
59011041020 |
OXYCONTIN 10MG TABLETS HUD 20S |
01/01/2021 |
4.34 |
91.11 |
03/29/2030 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health. |
| Rx0000056 |
Purdue Pharma LP |
03/31/2021 |
59011041510 |
OXYCONTIN 15MG TABLETS 100S |
01/01/2021 |
31.11 |
653.22 |
03/29/2030 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health. |
| Rx0000056 |
Purdue Pharma LP |
03/31/2021 |
59011041520 |
OXYCONTIN 15MG TABLETS HUD 20S |
01/01/2021 |
6.38 |
134.02 |
03/29/2030 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health. |
| Rx0000056 |
Purdue Pharma LP |
03/31/2021 |
59011042010 |
OXYCONTIN 20MG TABLETS 100S |
01/01/2021 |
39.41 |
827.51 |
03/29/2030 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health. |
| Rx0000056 |
Purdue Pharma LP |
03/31/2021 |
59011042020 |
OXYCONTIN 20MG TABLETS HUD 20S |
01/01/2021 |
8.08 |
169.74 |
03/29/2030 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health. |
| Rx0000056 |
Purdue Pharma LP |
03/31/2021 |
59011043010 |
OXYCONTIN 30MG TABLETS 100S |
01/01/2021 |
54.80 |
1150.85 |
03/29/2030 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health. |
| Rx0000056 |
Purdue Pharma LP |
03/31/2021 |
59011043020 |
OXYCONTIN 30MG TABLETS HUD 20S |
01/01/2021 |
11.24 |
236.12 |
03/29/2030 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health. |
| Rx0000056 |
Purdue Pharma LP |
03/31/2021 |
59011044010 |
OXYCONTIN 40MG TABLETS 100S |
01/01/2021 |
67.49 |
1417.19 |
08/24/2027 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health. |
| Rx0000056 |
Purdue Pharma LP |
03/31/2021 |
59011044020 |
OXYCONTIN 40MG TABLETS HUD 20S |
01/01/2021 |
13.84 |
290.59 |
08/24/2027 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health. |
| Rx0000056 |
Purdue Pharma LP |
03/31/2021 |
59011046010 |
OXYCONTIN 60MG TABLETS 100S |
01/01/2021 |
95.55 |
2006.51 |
08/24/2027 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health. |
| Rx0000056 |
Purdue Pharma LP |
03/31/2021 |
59011046020 |
OXYCONTIN 60MG TABLETS HUD 20S |
01/01/2021 |
19.60 |
411.65 |
08/24/2027 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health. |
| Rx0000056 |
Purdue Pharma LP |
03/31/2021 |
59011048010 |
OXYCONTIN 80MG TABLETS 100S |
01/01/2021 |
117.76 |
2472.94 |
08/24/2027 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health. |
| Rx0000056 |
Purdue Pharma LP |
03/31/2021 |
59011048020 |
OXYCONTIN 80MG TABLETS HUD 20S |
01/01/2021 |
24.16 |
507.29 |
08/24/2027 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health. |
| Rx0000342 |
PureTek Corporation |
09/30/2021 |
59088075900 |
Empricaine II, Lidocaine2.5%/Prilocaine 2.5% cream USP, 30 g + Occlusive Dressing, 6cm x 7cm, Sterile,Trans.w/frame in pouch |
09/17/2021 |
560.02 |
1820.00 |
None |
Single Source Drug |
98 |
None |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |